A citation-based method for searching scientific literature

Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
Times Cited: 113



Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó, Thomas Danne, Darren K McGuire, Jake A Kushner, Anne Peters, Paul Strumph. N. Engl. J. Med. 2017
Times Cited: 139




List of shared articles



Times cited

Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes.
Bryony E Langford, Marc Evans, Tao Haskins-Coulter, Molly O'Connor, Harriet E O Cant, Lucy A Eddowes, Christopher Edmonds, Amarjeet Tank. Diabetes Obes Metab 2020
1

Efficacy and Safety of SGLT2 Inhibitors in Type 1 Diabetes After the Introduction of an Off-Label Use Protocol for Clinical Practice.
Ane Bayona Cebada, Lía Nattero-Chávez, Sara Alonso Díaz, Héctor F Escobar-Morreale, Manuel Luque-Ramírez. Diabetes Technol. Ther. 2020
1


Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
Marc Evans, Debbie Hicks, Dipesh Patel, Vinod Patel, Phil McEwan, Umesh Dashora.  2020
4

Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.
Bruce A Perkins, Nima Soleymanlou, Julio Rosenstock, Jay S Skyler, Lori M Laffel, Karl-Heinz Liesenfeld, Dietmar Neubacher, Matthew M Riggs, Curtis K Johnston, Rena J Eudy-Byrne,[...]. Diabetes Obes Metab 2020
1

Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update.
Sanjay Kalra, Kimi K Shetty, Vertivel B Nagarajan, Jignesh K Ved.  2020
2


Non-insulin therapies in addition to insulin in Type 1 DM treatment.
Andrea Llano, Gerard A McKay. Br. Med. Bull. 2020
0

Sodium-glucose cotransporter 2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes.
Koki Chiba, Hiroshi Nomoto, Akinobu Nakamura, Kyu Yong Cho, Kumiko Yamashita, Yui Shibayama, Aika Miya, Hiraku Kameda, Yoshio Kurihara, Shin Aoki,[...]. J Diabetes Investig 2020
0

Expression of glucose transporters in duodenal mucosa of patients with type 1 diabetes.
Andrea Mario Bolla, Elena Butera, Silvia Pellegrini, Amelia Caretto, Riccardo Bonfanti, Raffaella Alessia Zuppardo, Graziano Barera, Giulia Martina Cavestro, Valeria Sordi, Emanuele Bosi. Acta Diabetol 2020
0

Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes.
Roselle A Herring, Fariba Shojaee-Moradie, Robert Garesse, Mary Stevenage, Nicola Jackson, Barbara A Fielding, Agampodi Mendis, Sigurd Johnsen, A Margot Umpleby, Melanie Davies,[...]. Diabetes Care 2020
0


SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects.
Birgit Janssens, Simon Caerels, Chantal Mathieu.  2020
1

A pilot study of the feasibility of empagliflozin in recent-onset type 1 diabetes.
John M Wentworth, Spiros Fourlanos, Peter G Colman, Leonard C Harrison.  2020
0

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Anne L Peters, Darren K McGuire, Thomas Danne, Jake A Kushner, Helena W Rodbard, Ketan Dhatariya, Sangeeta Sawhney, Phillip Banks, Wenjun Jiang, Michael J Davies,[...]. Diabetes Care 2020
0


SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus.
Angus Gill, Stephen P Gray, Karin A Jandeleit-Dahm, Anna M D Watson. Curr Diabetes Rev 2019
0

Adjunct Antihyperglycemic Agents in Overweight and Obese Adults With Type 1 Diabetes.
Diana Isaacs, Stephanie Yager, Marcie Parker, Lauren Wolfe, Jennifer Luxenburg, Sanela Lekic. Ann Pharmacother 2019
0


Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.
Maria J Pereira, Jan W Eriksson. Drugs 2019
18

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode,[...]. Diabetes Care 2019
56

New Medications for the Treatment of Diabetes.
Satish K Garg, Dominique Giordano. Diabetes Technol. Ther. 2019
0


Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari. Cardiovasc Diabetol 2019
18

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Thomas Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney,[...]. Diabetes Care 2019
19




What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
Jessica A Dominguez Rieg, Timo Rieg. Diabetes Obes Metab 2019
5

Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes.
Torben Biester, Olga Kordonouri, Thomas Danne. Diabetes Obes Metab 2019
4


SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution.
Joseph I Wolfsdorf, Robert E Ratner. Diabetes Care 2019
3

Role of Noninsulin Therapies in the Treatment of Type 1 Diabetes.
Sara E Lingow, Sandra D Burke, Amie D Brooks, Pat S Rafferty.  2019
0

Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes.
Bruce A Perkins, Julio Rosenstock, Jay S Skyler, Lori M Laffel, David Z Cherney, Chantal Mathieu, Christianne Pang, Richard Wood, Ona Kinduryte, Jyothis T George,[...]. Diabetes Care 2019
2



Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
Claire Baker, Suman Wason, Phillip Banks, Sangeeta Sawhney, Anna Chang, Thomas Danne, Diane Gesty-Palmer, Jake A Kushner, Darren K McGuire, Frank Mikell,[...]. Diabetes Obes Metab 2019
6

Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Thomas Danne, Jeremy Pettus, Andrea Giaccari, Bertrand Cariou, Helena Rodbard, Stuart A Weinzimer, Mireille Bonnemaire, Sangeeta Sawhney, John Stewart, Stella Wang,[...]. Diabetes Technol. Ther. 2019
3

Off-label prescription of SGLT-2 inhibitors to patients with type 1 diabetes: an online survey of diabetes specialists in Italy.
Marina Scavini, Federico Bertuzzi, Angela Girelli, Roberta Celleno, Chiara Molinari, Francesco Pio Tripodi, Milena Sira Zanon, Paolo Di Bartolo, Giuliana La Penna. Acta Diabetol 2019
0

Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes.
Reyhaneh Moradi-Marjaneh, Maryam Paseban, Amirhossein Sahebkar. Phytother Res 2019
2

Glycaemic variability: The under-recognized therapeutic target in type 1 diabetes care.
Emma G Wilmot, Pratik Choudhary, Lalantha Leelarathna, Mike Baxter. Diabetes Obes Metab 2019
3

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
Daniël H van Raalte, Petter Bjornstad, Frederik Persson, David R Powell, Rita de Cassia Castro, Ping Stella Wang, Minzhi Liu, Hiddo J L Heerspink, David Cherney. Diabetes Care 2019
7

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease.
Tamara Y Milder, Sophie L Stocker, Dorit Samocha-Bonet, Richard O Day, Jerry R Greenfield. Eur. J. Clin. Pharmacol. 2019
3

SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.
Simeon I Taylor, Jenny E Blau, Kristina I Rother, Amber L Beitelshees. Lancet Diabetes Endocrinol 2019
9

Optimizing Postprandial Glucose Management in Adults With Insulin-Requiring Diabetes: Report and Recommendations.
John Jack L Leahy, Grazia Aleppo, Vivian A Fonseca, Satish K Garg, Irl B Hirsch, Anthony L McCall, Janet B McGill, William H Polonsky.  2019
2

Empagliflozin in type 1 diabetes.
Chantal Mathieu, Laura Van Den Mooter, Bert Eeckhout.  2019
1

A review of sotagliflozin for use in type 1 diabetes.
Wesley Nuffer, Briana Williams, Jennifer M Trujillo.  2019
1

European Association for the Study of Diabetes 2017.
Ann M Carracher, Payal H Marathe, Kelly L Close. J Diabetes 2018
0

SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus.
Michael d'Emden, John Amerena, Gary Deed, Carol Pollock, Mark E Cooper. Diabetes Res. Clin. Pract. 2018
10

Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes.
Julie A Lovshin, Geneviève Boulet, Yuliya Lytvyn, Leif E Lovblom, Petter Bjornstad, Mohammed A Farooqi, Vesta Lai, Leslie Cham, Josephine Tse, Andrej Orszag,[...]. JCI Insight 2018
12